SummaryBackground and objectiveKisspeptin stimulates hypothalamic GnRH secretion resulting in gonadotrophin release and has potential as a future therapeutic. Chronic subcutaneous infusion of kisspeptin via a pump (similar to an insulin pump) may provide an alternative route of administration in the future. We investigated for the first time in humans, the gonadotrophin response to subcutaneous (SC) infusions of kisspeptin‐54 in healthy women. Women are markedly more responsive to exogenous kisspeptin in the late follicular phase preovulation when oestradiol levels are naturally high. Therefore, we further investigated whether there was a correlation between baseline oestradiol levels and LH response to kisspeptin.Design and patientsA prospective, single‐blinded placebo‐controlled study. Healthy women (n = 4) received an 8‐h SC infusion of kisspeptin‐54 0·1, 0·3 or 1·0 nmol/kg/h or saline in the early follicular phase of 4 separate menstrual cycles. Gonadotrophins and oestradiol were measured every 10 min during the infusions.ResultsSC infusion of kisspeptin‐54 increased LH and FSH. The LH response to SC infusion of kisspeptin‐54 (0·3 and 1·0 nmol/kg/h) positively correlated with baseline oestradiol levels (P < 0·001). Further statistical analyses showed that in the 1·0 nmol/kg/h group, a 100pmol/l rise in baseline oestradiol was associated with a 1·0 IU/l increase in LH.ConclusionsKisspeptin administered via a SC infusion could be a viable future therapeutic route of administration for patients with infertility. Baseline oestradiol levels may be an important determinant of the gonadotrophin response to kisspeptin treatment in women and should be taken into consideration when evaluating gonadotrophin response.
Clinicopathologic features of IgG/IgA pemphigus in comparison with classic (IgG) and IgA pemphigus
AbstractBackgroundThe pemphigus group is characterized by the presence of circulating immunoglobulins against desmosomes. IgG/IgA pemphigus is defined by the presence of IgG and IgA cell surface deposits upon direct immunofluorescence (DIF) and/or circulating IgG and IgA autoantibodies upon indirect immunofluorescence. Previous reports of patients with IgG/IgA pemphigus are sparse. Whether IgG/IgA pemphigus is best classified as a subtype of IgG (classic) pemphigus or IgA pemphigus, or as a distinct entity, has yet to be determined.ObjectivesWe compared the features of patients with IgG/IgA pemphigus to those of IgG pemphigus and IgA pemphigus.MethodsRetrospective clinicopathologic study of patients with IgG, IgG/IgA, and IgA pemphigus evaluated at our clinic (1993–2013).ResultsWe included 26, 13, and seven patients with IgG, IgG/IgA, and IgA pemphigus, respectively. Patients with IgG/IgA pemphigus did not differ significantly from patients with IgG pemphigus in terms of clinical and microscopic features, DIF findings, anti‐desmoglein antibody values, and treatments required. However, patients with IgG/IgA pemphigus were significantly different from patients with IgA pemphigus regarding intertriginous distribution (P = 0.038) and pustular lesions (P < 0.001), acantholysis (P = 0.043), and presence of intercellular C3 deposits on DIF (P < 0.001).ConclusionComparative clinicopathologic data imply that IgG/IgA pemphigus may best be regarded as a variant of IgG pemphigus and distinct from IgA pemphigus.
Kaposi varicelliform eruption in patients with autoimmune bullous dermatoses
AbstractBackgroundViral superinfection of skin affected by preceding dermatosis has been studied extensively in eczema and reported anecdotally in pemphigus. Little is known about its involvement and complications in patients with other immunobullous diseases.MethodsTo investigate clinical features and complications of viral superinfection in patients with immunobullous diseases, we performed a retrospective chart review.ResultsWe identified 12 patients with immunobullous diseases (linear immunoglobulin A bullous dermatosis, n = 2; pemphigoid, n = 3; pemphigus, n = 7) and superinfection by herpes simplex virus 1 (n = 9) or 2 (n = 3). Complications included inpatient hospitalization for intensive management of skin lesions during viral flare (n = 6), herpes keratitis (n = 1), and death due to sepsis (n = 1). Five patients previously had a skin swab negative for herpes simplex virus polymerase chain reaction before a positive test. Nine patients were taking systemic corticosteroids or corticosteroid‐sparing agents at herpetic infection; two with linear immunoglobulin A bullous dermatosis and one with a new diagnosis of pemphigus vulgaris had not.ConclusionsViral superinfection is a potentially serious complication in patients with immunobullous diseases. Clinicians should have a high index of suspicion for this phenomenon, even when patients are not otherwise immunosuppressed or when previous viral skin assays have been negative.
SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival
Context Health care trainees demonstrate implicit (automatic, unconscious) and explicit (conscious) bias against people from stigmatised and marginalised social groups, which can negatively influence communication and decision making. Medical schools are well positioned to intervene and reduce bias in new physicians. Objectives This study was designed to assess medical school factors that influence change in implicit and explicit bias against individuals from one stigmatised group: people with obesity. Methods This was a prospective cohort study of medical students enrolled at 49 US medical schools randomly selected from all US medical schools within the strata of public and private schools and region. Participants were 1795 medical students surveyed at the beginning of their first year and end of their fourth year. Web‐based surveys included measures of weight bias, and medical school experiences and climate. Bias change was compared with changes in bias in the general public over the same period. Linear mixed models were used to assess the impact of curriculum, contact with people with obesity, and faculty role modelling on weight bias change. Results Increased implicit and explicit biases were associated with less positive contact with patients with obesity and more exposure to faculty role modelling of discriminatory behaviour or negative comments about patients with obesity. Increased implicit bias was associated with training in how to deal with difficult patients. On average, implicit weight bias decreased and explicit bias increased during medical school, over a period of time in which implicit weight bias in the general public increased and explicit bias remained stable. Conclusions Medical schools may reduce students’ weight biases by increasing positive contact between students and patients with obesity, eliminating unprofessional role modelling by faculty members and residents, and altering curricula focused on treating difficult patients.
The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients
Abstract Introduction: Invasive lobular carcinoma (ILC) comprises approximately ∼10-20% of breast cancers (BC) and appears to have a distinct biology from invasive ductal carcinoma (IDC). ILC is known to have a higher incidence of multifocal (MF) disease when compared to IDC (Biglia N, EJSO, 2013) and in general, MF BC has been associated with an increased rate of regional lymph node metastases (Cabioglu N, JACS, 2009). Treatment decisions are most often defined by the largest of the MF tumors without targeting potentially relevant biologic heterogeneity of the disease. We conducted a genomic analysis of MF ILC to help address this knowledge void. Methods: We characterized gene expression in multiple foci from 11 patients (pts) with MF ILC (all ER+ and HER2-, mean number of foci = 2.62) and 13 benign breast tissues. RNA was extracted from 3×1.5mm cores from each foci and gene expression was measured in 730 known cancer genes using the NanoString PanCancer pathways panel. Differential gene expression analyses were performed between 1) MF tumors and benign tissue (BT) accounting for pairing of pts and 2) different foci of MF tumors from the same ILC pt by ANOVA. The association of clinical covariates (age, number of tumors, grade and stage) in the top genes that were differentially expressed between multiple foci was assessed by linear mixed models accounting for pt and tumor. Results: A total of 20 genes (including MET and EGFR, top 5 genes: SPRY2, SOX17, FIGF, PDGFA, IL6) were differentially expressed (p<0.05) between malignant foci from the same pt, after correction by false discovery rate (FDR). EGFR expression was also negatively associated with the number of positive lymph nodes (N1a vs N0 absolute fold change = 0.51, p = 0.043). We observed an excess of genes that were down-regulated in MF ILC compared to BT. 277 genes were differentially expressed at p<0.05 after correction by FDR. The top 5 differentially expressed genes (by fold change) between ILC and BT were COL11A1, COL1A1, WIF1, FIGF and PROM1. CDH1, a known marker of ILC, was down-regulated in ILC compared to benign (absolute fold change = 2.54, p = 6.02×10−6), ranked only 39/277 genes by fold change. MET and EGFR ranked 29 and 42/277 genes (p = 5.99×10−9 and 3.32×10−8 respectively). Conclusion: We observed significant heterogeneity for 20/730 genes between individual foci of MF ILC within the same pt suggesting that MF synchronous ILC lesions may have different biologic behavior. This in turn may have important prognostic implications with potential therapeutic utility. Our analyses also shows significant down-regulation of gene expression between ILC tumors and BT for many genes other than CDH1 suggesting that additional biomarkers can be used to further characterize ILC Study funded in part by Mayo Clinic Cancer Focus Research Team, the 26.2 with Donna Foundation and the Serene M. and Frances C. Durling endowment. Citation Format: Pooja Advani, Nadine Norton, Daniel J. Serie, Xochiquetzal Geiger, Julia E. Crook, Aubrey E. Thompson, Edith A. Perez, Alvaro Moreno Aspitia. Characterization of individual foci of multifocal invasive lobular breast cancer using gene expression profiling. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4761. doi:10.1158/1538-7445.AM2015-4761